DE3317280C2 - - Google Patents

Description

The invention relates to the use of isoxsuprine and / or a pharmaceutically acceptable derivative thereof, optionally together with usual pharmaceutical auxiliaries substances in the fight against scaphoid disease Horses.

The scaphoid disease shows up in an increasing and previously irreversible lameness, one or both fore runs of a horse and is increasingly affected stubborn gait is characterized. So far, was one of horses suffering from this disease are permanently unable to work.

The scaphoid disease is essentially for ischemic necrosis of the scaphoid within the Horse's hoof. It has been around since the end of the 19th century known and it was previously assumed that this was a Arthritis-type pathogenesis. It was also believed that scaphoid disease in horses is bad Blood flow to the scaphoid is due. Dementspre The treatment of this disease has been carried out to date oral administration of warfarin, an anticoagulant means that should serve, possibly occurred Dissolve blood clots and thereby increase blood circulation promote. However, this treatment has proven itself in practice proved unsuccessful as it carries the risk in itself holds that the horse treated in this way dies or is not used becomes bar and that even if this treatment there is an improvement after treatment has ended Illness recurs immediately. Other means of Improved blood flow did not get the desired one Result led.  

Also the assumption that vasodilatory treatment The scaphoid disease in horses is more suitable have not been confirmed in practice since the one appropriate vasodilatory drugs has brought the desired success.

The object of the invention was therefore to find a means with the help of which it is possible the scaphoid disease to treat horses effectively.

It has now surprisingly been found that isoxsuprine or Derivatives thereof, which already exist as GB-PS 12 18 102 Active substances in agents for oral administration for the Treatment of peripheral circulatory disorders (also arterioskle circulatory circulatory disorders of the extremities) has already been used in human medicine for which effective and permanent treatment of scaphoid disorders are excellent for horses.

The invention therefore relates to the use of isox suprin and / or a pharmaceutically acceptable derivative of these, in particular of isoxsuprine hydrochloride if together with common pharmaceutical excipients, in fighting scaphoid disease in horses.

Isoxsuprine hydrochloride is a known compound of the Formula C₁₈H₂₃NO₃ · HCl, the full name 1-p-hydroxyphenyl-2- (1-methyl-2-phenoxyethylamino) propane 1-ol hydrochloride and has the following structural formula

By processing isoxsuprine or a pharmaceutical compatible derivative thereof over a longer period of time  it is possible to have sciatic bone disease effective in horses and treat it permanently. The exact mechanism of the The effect of isoxsuprin is not yet known. It applies however, as certain that the effect of isoxsuprin is neither alone on a blood circulation-promoting effect a vasodilatory effect alone, because by bleeding or vasodilators in the practical treatment of scaphoid disease Horses have proven ineffective. So still have to other factors are added, but are not yet known are.

According to a preferred embodiment of the invention Isoxsuprine hydrochloride of the formula given above for Combat scaphoid disease used in horses.

The isoxsuprine used as active ingredient according to the invention or a derivative thereof is preferably in the form of a orally administrable preparation, in particular in the form of a orally injectable paste, or in the form of an edible pul verse before. For the treatment of scaphoid disease in horses the preparation is preferably over a longer period Period, especially twice a day for one Period of at least 21 days and especially over one beyond that in a smaller period administered daily dose.

If the preparation is in the form of a paste, contains these are preferably isoxsuprine hydrochloride, paraffin oil, Polysorbate 80, propyl paraben, methyl paraben, precipitated Silicon dioxide, flavor and water.

If the preparation is in the form of a powder, contains this is preferably isoxsuprine hydrochloride, cereal flour,  Lactose and talcum powder.

According to a particularly preferred embodiment of the Invention is isoxsuprine hydrochloride as an active stock part (active ingredient) in a pharmaceutically acceptable Paste used by the horse just before feeding for example 30 minutes beforehand, orally twice a day can be submitted.

The preferred dosage amount for each administration comprises 0.6 mg of active ingredient per kg Body weight and this dose can be administered for 21 days what the same daily dosage is about another period of 21 days, administered every other day. It follows that he high doses of isoxsuprine hydrochloride according to the invention be administered for a considerable period of time.

As usual, paste-like drugs can be used one in the side of a horse's empty mouth led syringe to be administered to the paste on the Apply the back of the tongue. When the syringe is out the horse's mouth should pull for a few seconds kept long closed to ensure that the full dose is swallowed.

It is believed that such treatment not in pregnant mares, after foals or after a recent arterial hemorrhage should be done.

A typical paste preparation for this Treatment can include the following ingredients, specified in Parts by weight, contain:

Isoxsuprine hydrochloride 40.0 Paraffin oil 610.5 Polysorbate 80 8.0 Propyl paraben 0.2 Methyl paraben 0.8 Sodium cyclamate 2.0 precipitated silica 163.0 Aniseed fragrance 1.5 Orange Color (C.I. 15985) 0.1 Water 142.5

Another type of treatment may use isoxsuprine hydrochloride can be incorporated into a powder preparation, that can be added to dry food, and a Typical preparation of this type can be found below given components, given in parts by weight, contain:

Isoxsuprine hydrochloride 100 Corn Flour636 Lactose224 Talc powder 40

It should be noted that the above Dosie quantities and dosing times are only examples represent and depending on the veterinarian in individual cases on the clinical course of the treated horse be placed.

As another clue to the results that are achieved can be, if the scaphoid disease in horses like is proposed below, the Course of experimental treatment of a group of 16 horses described in more detail.

For all horses was carried out in the course of routine diagnostic tests and radiographic procedures diagnosed with scaphoid disease. In particular all horses were paralyzed on one or at the beginning of treatment both forelegs and the lameness increased, which for the Scaphoid disease is typical after turning the Fetlock and phalangeal joint for a period of 1 minute. The lameness was removed by blocking the branches of the palmard digital nerves to the scaphoid and bursa under local anesthesia. X-rays taken from the upright foot position were shown to be usually triangular Vascular channels to form an inverted bottle (flask) were rounded.

As a result, the above diagnostic tests found that 16 of the initially paralyzing horses had a scaphoid disease and it became common with the daily Chen treatment with the paste preparation mentioned above in a dose of 0.6 mg / kg (isoxsuprine hydrochloride / Body weight) started twice a day. The dosage amount  was determined by clinical estimation by Er Increase the dose until the horses have a positive clinical Indicated reaction.

The dose was given to each horse for about 20 to 30 minutes administered before feeding.

The initial treatment period was 21 days. At however, some horses were found to be extended treatment usually struggles for periods of 21 days required.

For the horses that responded well to the initial therapy, treatment was at the end of the appropriate treatment period canceled. In 5 of the horses, however, the decrease was clinical symptoms delayed, although at the beginning of the Treatment showed an improvement.

Treatment was programmed with a withdrawal dose of 0.6 mg / kg once a day for 10 to 14 days, then 0.3 mg / kg stopped once a day for 7 to 10 days. The withdrawal program was introduced after the It was found that 4 horses had a relapse seemed if the treatment was suddenly stopped, when the paste supply ran out. With programmed withdrawal this phenomenon could be alleviated.

The response to the treatment was complete Success in 11 of the 16 cases (68.75%).

In the five cases where there is no complete besei clinical symptoms occurred, was found that scaphoid disease isn't the only cause was for lameness. With two of the remaining five horses there was no improvement in lameness after the Palmardigital nerve blockage, although by x-rays Changes related to scaphoid disease were shown. The lameness decreased with these horses,  however, they did not fully recover after the Nerve blockage gave no positive response. This probably indicates that other lameness problems associated with the scaphoid Illness existed.

Of course, the treatment described above can orally also in other forms of administration than in the form a paste or powder or in the form of granules Chen (granules) and it is assumed that suitable preparations also by injection or topically can be administered.

The invention has been made on the basis of before preferred treatment with isoxsuprine hydrochloride wrote, however, it is for the skilled person on this Area of course that instead of isoxsuprine hydrochloride also derivatives thereof, such as e.g. B. isoxsuprine lactate, isoxsuprine resinate and others closely related isoxsuprine compounds can be used can, which have similar pharmacological properties as Have isoxsuprine hydrochloride and when they are administered Similar benefits can also be expected.

Claims (1)

Use of isoxsuprine or a pharmaceutically acceptable one Lichen derivative thereof, if necessary together with usual pharmaceutical excipients, in combating the barge leg disease in horses.